Genetically attenuated Trypanosoma cruzi parasites as a potential vaccination tool

Bioengineered

Volumn 3, Issue 4, 2012, Pages

  Brandan, Cecilia Pérez ^a   Basombrío, Miguel Ángel ^a  

^a UNIVERSIDAD NACIONAL DE SALTA   (Argentina)

Author keywords

Chagas disease; Dhfr ts; Gene knockout; Trypanosoma cruzi

Indexed keywords

DIHYDROFOLATE REDUCTASE; GAMMA INTERFERON; THYMIDYLATE SYNTHASE; TRYPANOSOMA CRUZI VACCINE; LIVE VACCINE; PROTOZOAL PROTEIN; PROTOZOAL VACCINE;

ARTICLE; AUXOTROPHY; CD8+ T LYMPHOCYTE; CELL DIVISION; CELL PROLIFERATION; CELLULAR IMMUNITY; CHAGAS DISEASE; DNA SYNTHESIS; GENE DELETION; GENE DUPLICATION; GENE MUTATION; GENE TARGETING; GENETIC MANIPULATION; HUMORAL IMMUNITY; LEISHMANIA MAJOR; MICROBIAL ATTENUATION; NONHUMAN; PARASITE VIRULENCE; PHENOTYPE; PHENOTYPIC PLASTICITY; RNA INTERFERENCE; TRYPANOSOMA BRUCEI; TRYPANOSOMA CRUZI; VACCINATION; ANIMAL; DISEASE TRANSMISSION; DOG; ENZYMOLOGY; GENETIC ENGINEERING; GENETICS; HOMOLOGOUS RECOMBINATION; IMMUNOLOGY; METABOLISM; MOUSE; MUTATION; PARASITEMIA; PARASITOLOGY; PATHOGENICITY; VIRULENCE;

CANIS FAMILIARIS; MUS; TRYPANOSOMA CRUZI; TRYPANOSOMATIDAE;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CHAGAS DISEASE; DOGS; GENE DELETION; GENETIC ENGINEERING; HOMOLOGOUS RECOMBINATION; MICE; MUTATION; PARASITEMIA; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; TETRAHYDROFOLATE DEHYDROGENASE; TRYPANOSOMA CRUZI; VACCINES, ATTENUATED; VIRULENCE;

EID: 84875106425     PISSN: 19491018     EISSN: 19491026     Source Type: Journal    
DOI: 10.4161/b     Document Type: Article

References (42)

1. WHO/TDR. Epidemiology of Chagas' disease, past and present. Report of the Scientific Working Group on Chagas' disease 2007.
2. Fitchett JR, Cooke MK. Genetically engineered parasites: the solution to designing an effective malaria vaccine? Trends Parasitol 2010; 26:322-3; PMID:20537954; http://dx.doi.org/10.1016/j.pt.2010.04.008.
3. Vaughan AM, Wang R, Kappe SH. Genetically engineered, attenuated whole-cell vaccine approaches for malaria. Hum Vaccin 2010; 6:107-13; PMID:19838068; http://dx.doi.org/10.4161/hv.6.1.9654.
4. Silvestre R, Cordeiro-da-Silva A, Ouaissi A. Live attenuated Leishmania vaccines: a potential strategic alternative. Arch Immunol Ther Exp (Warsz) 2008; 56:123-6; PMID:18373245; http://dx.doi.org/10.1007/s00005-008-0010-9.
5. Barrio AB, Van Voorhis WC, Basombrío MA. Trypanosoma cruzi: attenuation of virulence and protective immunogenicity after monoallelic disruption of the cub gene. Exp Parasitol 2007; 117:382-9; PMID:17624327; http://dx.doi.org/10.1016/j.exppara.2007.05.005.
6. Collins MH, Craft JM, Bustamante JM, Tarleton RL. Oral exposure to Trypanosoma cruzi elicits a systemic CD8+ T cell response and protection against heterotopic challenge. Infect Immun 2011; 79:3397-406; PMID:21628516; http://dx.doi.org/10.1128/IAI.01080-10.
7. Perez Brandan C, Padilla AM, Xu D, Tarleton RL, Basombrio MA. Knockout of the dhfr-ts gene in Trypanosoma cruzi generates attenuated parasites able to confer protection against a virulent challenge. PLoS Negl Trop Dis 2011; 5:1418; PMID:22180798; http://dx.doi.org/10.1371/journal.pntd.0001418.
8. Zago MP, Barrio AB, Cardozo RM, Duffy T, Schijman AG, Basombrío MA. Impairment of infectivity and immunoprotective effect of a LYT1 null mutant of Trypanosoma cruzi. Infect Immun 2008; 76:443-51; PMID:17938222; http://dx.doi.org/10.1128/IAI.00400-07.
9. Gómez ND, Safeukui I, Adelani AA, Tewari R, Reddy JK, Rao S, et al. Deletion of a malaria invasion gene reduces death and anemia, in model hosts. PLoS One 2011; 6:25477; PMID:21980474; http://dx.doi.org/10.1371/journal.pone.0025477.
10. Manthri S, Güther ML, Izquierdo L, Acosta-Serrano A, Ferguson MA. Deletion of the TbALG3 gene demonstrates site-specific N-glycosylation and N-glycan processing in Trypanosoma brucei. Glycobiology 2008; 18:367-83; PMID:18263655; http://dx.doi.org/10.1093/glycob/cwn014.
11. Munday JC, McLuskey K, Brown E, Coombs GH, Mottram JC. Oligopeptidase B deficient mutants of Leishmania major. Mol Biochem Parasitol 2011; 175:49-57; PMID:20883728; http://dx.doi.org/10.1016/j.molbiopara.2010.09.003.
12. Ajioka J, Swindle J. The calmodulin-ubiquitin (CUB) genes of Trypanosoma cruzi are essential for parasite viability. Mol Biochem Parasitol 1996; 78:217-25; PMID:8813691; http://dx.doi.org/10.1016/S0166-6851(96)02627-8.
13. Allaoui A, François C, Zemzoumi K, Guilvard E, Ouaissi A. Intracellular growth and metacyclogenesis defects in Trypanosoma cruzi carrying a targeted deletion of a Tc52 protein-encoding allele. Mol Microbiol 1999; 32:1273-86; PMID:10383767; http://dx.doi.org/10.1046/j.1365-2958.1999.01440.x.
14. Annoura T, Nara T, Makiuchi T, Hashimoto T, Aoki T. The origin of dihydroorotate dehydrogenase genes of kinetoplastids, with special reference to their biological significance and adaptation to anaerobic, parasitic conditions. J Mol Evol 2005; 60:113-27; PMID:15696374; http://dx.doi.org/10.1007/s00239-004-0078-8.
15. Caler EV, Vaena de Avalos S, Haynes PA, Andrews NW, Burleigh BA. Oligopeptidase B-dependent signaling mediates host cell invasion by Trypanosoma cruzi. EMBO J 1998; 17:4975-86; PMID:9724634; http://dx.doi.org/10.1093/emboj/17.17.4975.
16. Campos PC, Silva VG, Furtado C, Machado-Silva A, Darocha WD, Peloso EF, et al. Trypanosoma cruzi MSH2: Functional analyses on different parasite strains provide evidences for a role on the oxidative stress response. Mol Biochem Parasitol 2011; 176:8-16; PMID:21073906; http://dx.doi.org/10.1016/j.molbiopara.2010.11.001.
17. Conte I, Labriola C, Cazzulo JJ, Docampo R, Parodi AJ. The interplay between folding-facilitating mechanisms in Trypanosoma cruzi endoplasmic reticulum. Mol Biol Cell 2003; 14:3529-40; PMID:12972544; http://dx.doi.org/10.1091/mbc.E03-04-0228.
18. Cooper R, de Jesus AR, Cross GA. Deletion of an immunodominant Trypanosoma cruzi surface glycoprotein disrupts flagellum-cell adhesion. J Cell Biol 1993; 122:149-56; PMID:8314840; http://dx.doi.org/10.1083/jcb.122.1.149.
19. de Souza FS, Rampazzo Rde C, Manhaes L, Soares MJ, Cavalcanti DP, Krieger MA, et al. Knockout of the gene encoding the kinetoplast-associated protein 3 (KAP3) in Trypanosoma cruzi: effect on kinetoplast organization, cell proliferation and differentiation. Mol Biochem Parasitol 2010; 172:90-8; PMID:20363262; http://dx.doi.org/10.1016/j.molbiopara.2010.03.014.
20. Gluenz E, Taylor MC, Kelly JM. The Trypanosoma cruzi metacyclic-specific protein Met-III associates with the nucleolus and contains independent amino and carboxyl terminal targeting elements. Int J Parasitol 2007; 37:617-25; PMID:17239886; http://dx.doi.org/10.1016/j.ijpara.2006.11.016.
21. MacRae JI, Obado SO, Turnock DC, Roper JR, Kierans M, Kelly JM, et al. The suppression of galactose metabolism in Trypanosoma cruzi epimastigotes causes changes in cell surface molecular architecture and cell morphology. Mol Biochem Parasitol 2006; 147:126-36; PMID:16569451; http://dx.doi.org/10.1016/j.molbiopara.2006.02.011.
22. Manning-Cela R, Cortés A, González-Rey E, Van Voorhis WC, Swindle J, González A. LYT1 protein is required for efficient in vitro infection by Trypanosoma cruzi. Infect Immun 2001; 69:3916-23; PMID:11349059; http://dx.doi.org/10.1128/IAI.69.6.3916-23.2001.
23. Serpeloni M, Moraes CB, Muniz JR, Motta MC, Ramos AS, Kessler RL, et al. An essential nuclear protein in trypanosomes is a component of mRNA transcription/export pathway. PLoS One 2011; 6:20730; PMID:21687672; http://dx.doi.org/10.1371/journal.pone.0020730.
24. Wilkinson SR, Taylor MC, Horn D, Kelly JM, Cheeseman I. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc Natl Acad Sci USA 2008; 105:5022-7; PMID:18367671; http://dx.doi.org/10.1073/pnas.0711014105.
25. Xu D, Brandán CP, Basombrío MA, Tarleton RL. Evaluation of high efficiency gene knockout strategies for Trypanosoma cruzi. BMC Microbiol 2009; 9:90;PMID:19432966; http://dx.doi.org/10.1186/1471-2180-9-90.
26. Ivanetich KM, Santi DV. Bifunctional thymidylate synthase-dihydrofolate reductase in protozoa. FASEB J 1990; 4:1591-7; PMID:2180768.
27. Cruz A, Coburn CM, Beverley SM. Double targeted gene replacement for creating null mutants. Proc Natl Acad Sci USA 1991; 88:7170-4; PMID:1651496; http://dx.doi.org/10.1073/pnas.88.16.7170.
28. Sienkiewicz N, Jarosławski S, Wyllie S, Fairlamb AH. Chemical and genetic validation of dihydrofolate reductase-thymidylate synthase as a drug target in African trypanosomes. Mol Microbiol 2008; 69:520-33; PMID:18557814; http://dx.doi.org/10.1111/j.1365-2958.2008.06305.x.
29. Cruz AK, Titus R, Beverley SM. Plasticity in chromosome number and testing of essential genes in Leishmania by targeting. Proc Natl Acad Sci USA 1993; 90:1599-603; PMID:8381972; http://dx.doi.org/10.1073/pnas.90.4.1599.
30. Mukherjee A, Langston LD, Ouellette M. Intrachromosomal tandem duplication and repeat expansion during attempts to inactivate the subtelomeric essential gene GSH1 in Leishmania. Nucleic Acids Res 2011; 39:7499-511; PMID:21693561; http://dx.doi.org/10.1093/nar/gkr494.
31. Titus RG, Gueiros-Filho FJ, de Freitas LA, Beverley SM. Development of a safe live Leishmania vaccine line by gene replacement. Proc Natl Acad Sci USA 1995; 92:10267-71; PMID:7479765; http://dx.doi.org/10.1073/pnas.92.22.10267.
32. Bustamante JM, Bixby LM, Tarleton RL. Druginduced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease. Nat Med 2008; 14:542-50; PMID:18425131; http://dx.doi.org/10.1038/nm1744.
33. CDC, Ed. Epidemiology and Prevention of Vaccine-Preventable Diseases. Atlanta, Georgia 2012.
34. Dhillon S, Curran MP. Live attenuated measles, mumps, rubella and varicella zoster virus vaccine (Priorix-Tetra). Paediatr Drugs 2008; 10:337-47; PMID:18754700; http://dx.doi.org/10.2165/00148581-200810050-00007.
35. McShane H. Tuberculosis vaccines: beyond bacilli Calmette-Guerin. Philos Trans R Soc Lond B Biol Sci 2011; 366:2782-9; PMID:21893541; http://dx.doi.org/10.1098/rstb.2011.0097.
36. Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, Masopust D, et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 2008; 28:710-22; PMID:18468462; http://dx.doi.org/10.1016/j.immuni.2008.02.020.
37. Padilla AM, Bustamante JM, Tarleton RL. CD8+ T cells in Trypanosoma cruzi infection. Curr Opin Immunol 2009; 21:385-90; PMID:19646853; http://dx.doi.org/10.1016/j.coi.2009.07.006.
38. Martin DL, Weatherly DB, Laucella SA, Cabinian MA, Crim MT, Sullivan S, et al. CD8+ T-Cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes. PLoS Pathog 2006; 2:77; PMID:16879036; http://dx.doi.org/10.1371/journal.ppat.0020077.
39. Basombrío MA, Besuschio S. Trypanosoma cruzi culture used as vaccine to prevent chronic Chagas' disease in mice. Infect Immun 1982; 36:351-6; PMID:6804390.
40. Basombrío MA, Arredes H, Uncos DA, Rossi R, Alvarez E. Field trial of vaccination against American trypanosomiasis (Chagas' disease) in domestic guinea pigs. Am J Trop Med Hyg 1987; 37:57-62; PMID:3111281.
41. Basombrio MA, Segura MA, Mora MC, Gomez L. Field trial of vaccination against American trypanosomiasis (Chagas' disease) in dogs. Am J Trop Med Hyg 1993; 49:143-51; PMID:8352387.
42. Canavaci AM, Bustamante JM, Padilla AM, Perez Brandan CM, Simpson LJ, Xu D, et al. In vitro and in vivo high-throughput assays for the testing of anti-Trypanosoma cruzi compounds. PLoS Negl Trop Dis 2010; 4:740; PMID: 20644616; http://dx.doi.org/10.1371/journal.pntd.0000740.